New study for those with heart disease and excess weight
Please fill in your details
About the Study
This study is for people living with obesity and heart disease. Participants will start either a once weekly injection of CagriSema or placebo to their current treatment. CagriSema is a combination medication of Cagrilinitide and Semaglutide. Cagrilinitide is an investigational once-weekly injection, and Semaglutide is an FDA approved once-weekly injection (Ozempic).
The goal of the study is to assess the safety of CagriSema in people living with obesity and cardiovascular disease.
Participants will receive the study med at no charge, and will be compensated for their time and travel.
Participant Eligibility Criteria ( To take part in the study )
- 55 years of age and older
- Have obesity
- History of heart attack, stroke or arterial disease